Forwarded from اتچ بات
📎📒📕📗📔
🗒به روز رسانی #اطلاعات
📚 #دانلود_مقاله
💻👉👉#DOWNLOAD PDF
✅ Diagnosis and treatment of left ventricular dysfunction
and heart failure in cancer patients
#ESC Journals, E-Journal of Cardiology Practice, Volume-16
Vol. 16, N° 40 - 27 Feb 2019
Dr. Alexander R. Lyon , FHFA, Dr. Mohsen Habibian, Dr. Ruben Evertz, Dr. Riccardo Asteggiano , Prof. Thomas M. Suter
📌#دانلود کامل در فایل پیوست 👇👇👇
🖥 https://bit.ly/2MmK1tU
✨ Join Us✨
📲 @IRathero 💫
🗒به روز رسانی #اطلاعات
📚 #دانلود_مقاله
💻👉👉#DOWNLOAD PDF
✅ Diagnosis and treatment of left ventricular dysfunction
and heart failure in cancer patients
#ESC Journals, E-Journal of Cardiology Practice, Volume-16
Vol. 16, N° 40 - 27 Feb 2019
Dr. Alexander R. Lyon , FHFA, Dr. Mohsen Habibian, Dr. Ruben Evertz, Dr. Riccardo Asteggiano , Prof. Thomas M. Suter
📌#دانلود کامل در فایل پیوست 👇👇👇
🖥 https://bit.ly/2MmK1tU
✨ Join Us✨
📲 @IRathero 💫
Telegram
attach 📎
🌎🌎🌎
📚 به روز رسانی #اطلاعات 📕📖
✅ Important Interventional Trials From #ESC #Congress 2019: The THEMIS-PCI
🔸The THEMIS-PCI (Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention) report in Lancet1 found that the primary efficacy outcome (a composite of cardiovascular death, myocardial infarction [MI], or stroke) was lower in patients randomized to ticagrelor than to placebo (404 [7.3%] of 5,558 vs. 480 [8.6%] of 5,596; hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.74-0.97; p = 0.013) in the subgroup of patients with a history of PCI.2 However, THEMIS-PCI has major statistical flaws that limit its generalizability:
1.This was a subgroup analysis. The lay press understands that subdividing a main trial into subgroups is limiting because it introduces spurious results.
2.The p-value describing the interaction between PCI and non-PCI patients for the primary outcome was not significant (p = 0.16). ...
🔸 #Read_more 👇
💻 https://bit.ly/2PKTQFI
💻 https://bit.ly/2qiCEMT
✨ Join Us✨
📲 @IRathero 💫
📚 به روز رسانی #اطلاعات 📕📖
✅ Important Interventional Trials From #ESC #Congress 2019: The THEMIS-PCI
🔸The THEMIS-PCI (Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention) report in Lancet1 found that the primary efficacy outcome (a composite of cardiovascular death, myocardial infarction [MI], or stroke) was lower in patients randomized to ticagrelor than to placebo (404 [7.3%] of 5,558 vs. 480 [8.6%] of 5,596; hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.74-0.97; p = 0.013) in the subgroup of patients with a history of PCI.2 However, THEMIS-PCI has major statistical flaws that limit its generalizability:
1.This was a subgroup analysis. The lay press understands that subdividing a main trial into subgroups is limiting because it introduces spurious results.
2.The p-value describing the interaction between PCI and non-PCI patients for the primary outcome was not significant (p = 0.16). ...
🔸 #Read_more 👇
💻 https://bit.ly/2PKTQFI
💻 https://bit.ly/2qiCEMT
✨ Join Us✨
📲 @IRathero 💫
Iranian Society of Atherosclearosis
Important Interventional Trials From ESC Congress 2019: The THEMIS-PCI
The THEMIS-PCI (Ticagrelor in patients with diabetes and stable coronary artery disease with ...